Published online before print October 13, 2005, doi: 10.1161/01.STR.0000185718.26377.07
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:2410.)
© 2005 American Heart Association, Inc.
Original Contributions |
Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
From the Department of Biostatistics, Bioinformatics & Epidemiology (Y.Y.P., B.C.T., R.W.), Medical University of South Carolina, Charleston, SC; Trout Centre at Irish Lake (D.L.S.), Canada; and the Department of Neurology and Health Evaluation Sciences (K.C.J.), University of Virginia.
Correspondence to Yuko Y. Palesch, PhD, Department of Biostatistics, Bioinformatics & Epidemiology, Medical University of South Carolina, P.O. Box 250835, 135 Cannon St, Suite 303, Charleston, SC 29425. E-mail paleschy{at}musc.edu
Background and Purpose— Most large, randomized phase III efficacy trials of therapeutic agents in ischemic stroke have failed to find treatment benefit. We determined whether some phase III studies could have been avoided if preceded by smaller single-arm phase II studies to evaluate the futility of proceeding to phase III.
Methods— To provide examples of the application of phase II methodology, we obtained primary outcome data for the active treatment group of 6 phase III ischemic stroke therapy trials. For each study, we estimated the sample size number required for a multistage single-arm study using parameters specified in the original study. We evaluated outcome data for the first number of subjects in the phase III study treatment arm ordered by enrollment dates. We compared the proportion of favorable outcomes to prespecified stopping criteria derived from a single-arm phase II futility design. If the observed proportion of favorable outcomes was less than the stopping criterion, we declared the treatment not sufficiently effective to warrant further evaluation in phase III.
Results— We identified 3 trials as futile in phase II; none of 3 showed treatment efficacy in phase III. In the 3 remaining phase II trials in which we did not show futility, one showed efficacy in phase III.
Conclusion— Single-arm phase II futility studies have been underused in stroke research, but provide a strategy for discarding treatments likely to be ineffective in phase III trials.
Key Words: clinical trials, phase II • ischemia • stroke
Related Article:
Stroke 2005 36: 2331-2332.
This article has been cited by other articles:
 |
|
 |
|
  J J. Lee and D. D Liu A predictive probability design for phase II cancer clinical trials Clinical Trials, April 1, 2008; 5(2): 93 - 106. [Abstract] [PDF]
|
|
|
|
 |
|
 B. C. Tilley and W. R. Galpern Screening Potential Therapies: Lessons Learned From New Paradigms Used in Parkinson Disease Stroke, February 1, 2007; 38(2): 800 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Cheung, P. H. Gordon, and B. Levin Selecting promising ALS therapies in clinical trials Neurology, November 28, 2006; 67(10): 1748 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Czaplinski, L. J. Haverkamp, A. A. Yen, E. P. Simpson, E. C. Lai, and S. H. Appel The value of database controls in pilot or futility studies in ALS Neurology, November 28, 2006; 67(10): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Tilley, Y. Y. Palesch, K. Kieburtz, B. Ravina, P. Huang, J. J. Elm, K. Shannon, G. F. Wooten, C. M. Tanner, G. C. Goetz, et al. Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs Neurology, March 14, 2006; 66(5): 628 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Levy, P. Kaufmann, R. Buchsbaum, J. Montes, A. Barsdorf, R. Arbing, V. Battista, X. Zhou, H. Mitsumoto, B. Levin, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS Neurology, March 14, 2006; 66(5): 660 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Levin The Utility of Futility Stroke, November 1, 2005; 36(11): 2331 - 2332. [Full Text] [PDF]
|
|